Sunshine Biopharma (SBFM) Income from Continuing Operations: 2011-2025
Historic Income from Continuing Operations for Sunshine Biopharma (SBFM) over the last 13 years, with Sep 2025 value amounting to -$883,820.
- Sunshine Biopharma's Income from Continuing Operations rose 26.21% to -$883,820 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.0 million, marking a year-over-year decrease of 41.81%. This contributed to the annual value of -$5.1 million for FY2024, which is 13.94% down from last year.
- According to the latest figures from Q3 2025, Sunshine Biopharma's Income from Continuing Operations is -$883,820, which was up 50.09% from -$1.8 million recorded in Q2 2025.
- Sunshine Biopharma's 5-year Income from Continuing Operations high stood at $667,116 for Q4 2021, and its period low was -$23.5 million during Q4 2022.
- Its 3-year average for Income from Continuing Operations is -$1.2 million, with a median of -$1.2 million in 2024.
- Within the past 5 years, the most significant YoY rise in Sunshine Biopharma's Income from Continuing Operations was 161.55% (2021), while the steepest drop was 6,461.84% (2021).
- Quarterly analysis of 5 years shows Sunshine Biopharma's Income from Continuing Operations stood at $667,116 in 2021, then crashed by 3,624.47% to -$23.5 million in 2022, then soared by 94.68% to -$1.3 million in 2023, then crashed by 72.65% to -$2.2 million in 2024, then grew by 26.21% to -$883,820 in 2025.
- Its last three reported values are -$883,820 in Q3 2025, -$1.8 million for Q2 2025, and -$1.2 million during Q1 2025.